DR. ALBERT SATTIN, MD
Psychiatric at Wilshire Blvd, Los Angeles, CA
License number
California C21283
Category
Psychiatric
Type
Psychiatry
Address
Address
11301 Wilshire Blvd, Los Angeles, CA 90073
Phone
(310) 268-4440
Personal information
See more information about ALBERT SATTIN at radaris.comName
Address
Phone
1811 Barry Ave, Los Angeles, CA 90025
1811 Barry Ave, Los Angeles, CA 90025
Professional information
See more information about ALBERT SATTIN at trustoria.com
Dr. Albert Sattin, Los Angeles CA - MD (Doctor of Medicine)
Dr. Albert Sattin, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
11301 Wilshire Blvd, Los Angeles 90073
(310) 268-4440 (Phone)
(310) 268-4440 (Phone)
Certifications:
Psychiatry, 1979
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Case Western Reserve University School of Medicine
Graduated: 1957
Barnes-Jewish Hospital
University Hospitals Of Cleveland
Inst Psych
Case Western Reserve University School of Medicine
Graduated: 1957
Barnes-Jewish Hospital
University Hospitals Of Cleveland
Inst Psych
Use Of Pyroglutamyl-Glutamyl-Prolyl Amide (Eep) For Neurological And Neurobehavioral Disorders
Use Of Pyroglutamyl-Glutamyl-Prolyl Amide (Eep) For Neurological And Neurobehavioral Disorders
US Patent:
6475989, Nov 5, 2002
Filed:
Oct 9, 1998
Appl. No.:
09/169657
Inventors:
Albert Sattin - Los Angeles CA 90025
Albert E. Pekary - Culver City CA 90230
Robert L. Lloyd - Duluth MN 55805
Albert E. Pekary - Culver City CA 90230
Robert L. Lloyd - Duluth MN 55805
International Classification:
A61K 3806
US Classification:
514 18, 530331
Abstract:
A tri-peptide drug for treatment of neurological and neurobehavioral disorders of a mammal, such drug being derived from the following formula: pGlu-X-Pro-NH , wherein the internal amino acid (X) is a non-histadine amino acid. Methods of treatment of neurological disorders using the tri-peptide, including as an adjunct, synergist or stand-alone therapy, in oral, parenteral, intranasal, transcutaneous, or rectal forms.
Tri-Peptides For Neurological And Neurobehavior Applications
Tri-Peptides For Neurological And Neurobehavior Applications
US Patent:
2002015, Oct 17, 2002
Filed:
Nov 14, 2001
Appl. No.:
10/002878
Inventors:
Albert Sattin - Los Angeles CA, US
Albert Pekary - Culver City CA, US
Robert Lloyd - Duluth MN, US
Albert Pekary - Culver City CA, US
Robert Lloyd - Duluth MN, US
International Classification:
A61K038/06, C07K005/08
US Classification:
514/018000, 530/331000
Abstract:
Provided are pharmaceutical preparations including a manufactured peptide having the formula pGlu-R-Pro, wherein Ris Glu, Phe, Leu, Tyr or Val, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, and methods of treatment of neurological and neurobehavioral disorders therewith.
Tri-Peptides For Neurological And Neurobehavioral Applications
Tri-Peptides For Neurological And Neurobehavioral Applications
US Patent:
2005000, Jan 13, 2005
Filed:
Aug 18, 2004
Appl. No.:
10/922476
Inventors:
Albert Sattin - Los Angeles CA, US
Albert Pekary - Culver City CA, US
Robert Lloyd - Duluth MN, US
Albert Pekary - Culver City CA, US
Robert Lloyd - Duluth MN, US
International Classification:
A61K038/05
US Classification:
514018000, 530331000
Abstract:
Provided are methods of treatment of neurological and neurobehavioral disorders utilizing pharmaceutical preparations including a manufactured peptide having the formula pGlu-R-Pro, wherein Ris Glu, Phe, Leu, Tyr or Val, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
Tri-Peptides For Antidepressant Applications
Tri-Peptides For Antidepressant Applications
US Patent:
2005023, Oct 20, 2005
Filed:
Sep 13, 2004
Appl. No.:
10/940202
Inventors:
Albert Sattin - Los Angeles CA, US
Albert Pekary - Culver City CA, US
Robert Lloyd - Duluth MN, US
Albert Pekary - Culver City CA, US
Robert Lloyd - Duluth MN, US
International Classification:
A61K038/05
US Classification:
514018000
Abstract:
Provided are methods of treatment of neurological and neurobehavioral disorders, including antidepressants for use in treatment of depression and related disorders, utilizing pharmaceutical preparations including a manufactured peptide having the formula pGlu-R-Pro, wherein Ris Glu, Phe, Leu, Tyr, Lys or Val, and preferably Gly, Lys, Leu or Val, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.